Houston biotech company gets green light from FDA to test coronavirus-fighting drug

clinical trials bound

Pulmotect is headed to clinical trials to verify how its drug fights against COVID-19. Getty Images

Houston biotech company Pulmotect Inc. has embarked on two clinical drug trials that could create weapons for the battle against the novel coronavirus.

Pulmotect gained permission from the U.S. Food and Drug Administration to test its inhaled drug, PUL-042, as a way to prevent coronavirus infections and to slow the early progression of COVID-19, the potentially fatal disease caused by the novel coronavirus. Pulmotect developed PUL-042 to activate the lungs' front-line defense against respiratory infections, and now it's being enlisted in the race to devise coronavirus treatments and cures.

"We have demonstrated PUL-042's unique ability to stimulate the immune system in the lungs to protect against a wide range of pathogens in multiple animal models," Dr. Colin Broom, CEO of Pulmotect, says in a May 7 release. "Pulmotect is optimistic that its immune-stimulating technology could be useful in mitigating the threats of [the coronavirus] and future emerging pathogens, and protecting vulnerable populations."

Unlike a vaccine, which typically takes 10 to 15 years to bring to the market, PUL-042 promises much faster deployment as scientists and health care workers wage war against COVID-19.

Each of the two clinical trials, both in the second phase, is being conducted at 10 sites across the U.S., including locations in Houston. In all, 20 sites are participating. Money for the trials came from the company's recently completed $12 million round of series B funding.

Pulmotect's partner in the trials is Covington, Kentucky-based CTI Clinical Trial and Consulting Services Inc. PARI Respiratory Equipment Inc., whose North American headquarters is in Midlothian, Virginia, is supplying medical equipment known as nebulizers to administer Pulmotect's inhaled drug.

"Both clinical trials are placebo-controlled to objectively evaluate safety and efficacy," Broom says in a May 5 release.

"In the first study, up to four doses of PUL-042 or placebo will be administered to 200 subjects by inhalation over a 10-day period to evaluate the prevention of infection and reduction in severity of COVID-19. In the second study, 100 patients with early symptoms of COVID-19 will receive the treatment administered up to three times over six days. In both trials, subjects will be followed up for 28 days to assess the effectiveness and tolerability of PUL-042."

Previous experiments conducted by Pulmotect indicate PUL-042 effectively protects mice against severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which are caused by coronaviruses that differ from the COVID-19 virus. Researchers performed those tests at the University of Texas Medical Branch at Galveston.

PUL-042 initially was developed to fight respiratory problems in cancer patients undergoing chemotherapy, which weakens the immune system. But the drug offers the potential to prevent or treat an array of respiratory infections caused by viruses, bacteria, or fungi.

"We have always considered PUL-042 to have the potential for the prevention and treatment of emerging epidemics and pandemics like the one we currently face," Broom says.

A separate trial of PUL-042 is underway in London. There, the drug is being tested on patients with chronic obstructive pulmonary disease (COPD) who are susceptible to lung infections. COPD is an inflammatory disease that blocks airflow from the lungs. People with COPD face a heightened risk of conditions like heart disease and lung cancer, the Mayo Clinic says.

Researchers at MD Anderson Cancer Center and Texas A&M University invented Pulmotect's PUL-042, which holds patents in 10 countries. Pulmotect, founded in 2007, emerged from Houston's Fannin Innovation Studio, which fosters early stage companies in the life sciences sector.

These Houston startups have created health care-related solutions amid the coronavirus outbreak. Getty Images

These 7 Houston health tech companies are providing COVID-19 solutions

startups to the rescue

It's all hands on deck in Houston in the battle against coronavirus — and local biotech startups have risen to the occasion.

From mental health solutions and online portals to virtual medicine and new treatments, these Houston companies have recently launched or pivoted to new options in health care.

Mental Health Match

Ryan Schwartz is offering free counseling to Texans. Photo courtesy of Mental Health Match

Mental Health Match, a Houston-based startup that uses tech to easily connect people to mental health professionals, has announced the opportunity for 100 Texas residents to get their first appointment free and remotely.

The company cites data that shows:

A 78 percent increase in Texans who are concerned about their marriage
A 71 percent increase in Texans concerned with their parenting or their children
A 35 percent spike in Texans feeling panicked

"You might be practicing social distancing, but you are not alone. It is easier to make it through this together if you can get support and guidance from a skilled professional. That's why we're working with therapists across Texas to provide a free session to individuals who need it most," says Ryan Schwartz, founder of Mental Health Match, in a news release.

Texans can apply for the free sessions online on a first-come, first-served basis.

Medical Informatics Corp.

Medical Informatics Corp.'s Sickbay platform can monitor patients from afar. Photo via michealthcare.com

Houston-based Medical Informatics has created a virtual ICU program, called Sickbay, and the tech tool is being used to remotely monitor patients in Houston Methodist. The program works around the clock from a control hub to use artificial intelligence and algorithms to monitor patients.

The company, which recently moved into its office in TMCx+, announced major growth in January, just ahead of the coronavirus outbreak.

"We designed our Sickbay platform to give lost data back to doctors, nurses and other members of the care team so they could save more lives," says Vincent Gagne, vice president of product for MIC, in a news release. "In fact, our apps are built in collaboration with our clients, such as Texas Children's Hospital and Houston Methodist. Having these facilities blocks away from our headquarters accelerates that collaboration and development."

MolecularMatch

MolecularMatch is bringing together COVID-19 information and trials. Photo via molecularmatch.com

MolecularMatch, a Houston startup focused on clinical informatics, has launched a free portal that accumulates research and clinical trials for COVID-19. The company is a tenant of TMCx+ and a portfolio company of Houston-based venture capital group GOOSE.

"The number of therapeutic cures and vaccines being tested are growing at an astounding rate," says Eric Pulaski, CEO at MolecularMatch, in a news release. "Our tools make it easier for clinicians and patients to find the help they need. Hopefully, we can help save lives by shortening the time it takes to get more patients into clinical trials and by speeding up research to find cures and vaccines."

The product uses the company's artificial intelligence-backed curation platform and is updated every two to three days.

Luminare

Luminare Inc. pivoted to quickly create an online COVID-19 screening tool, and local governments have tapped into the resource. Andriy Onufriyenko/Getty Images

Founded in 2014, Houston-based health care software startup Luminare Inc. seeks to prevent sepsis, a life-threatening reaction to a host of infections that causes about one-third of U.S. hospital deaths. Recently, though, Luminare pivoted to address another health concern — the threat of the novel coronavirus.

After the novel coronavirus surfaced, Luminare retooled its sepsis-detection platform to create a free online self-assessment test for people who suspect they've contracted the virus. The test, available at CheckForCorona.com, helps someone figure out whether they should seek a coronavirus test.

An online screening typically takes less than two minutes. The confidential, secure assessment complies with guidelines from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Based on your assessment results, you might be directed to contact your local health department or, in the worst-case scenario, call 911. Click here to read more.

Manatee

Manatee users can sign up for three months free. Photo via getmanatee.com

Denver-based Manatee was just announced to be selected for the 2020 TMCx cohort, and — while programming is beginning virtually — the startup will be enroute to Houston as soon as it's safe. Manatee focuses on providing connected, everyday therapy for kids.

In light of the effects of COVID-19 on both parents and children, Manatee has allowed users to register for three months free. Individuals can apply online.

Moleculin Biotech Inc.

Houston-based Moleculin, which works on oncology treatment, has filed a patent for its treatment to battle the coronavirus. Getty Images

Houston-based Moleculin Biotech Inc., a clinical stage pharmaceutical company that typically focuses on cancer treatment, announced that it has filed for a new patent for its use of one of its products to be used against the coronavirus and other potential viruses.

This patent application is for Moleculin's WP1122, and the company has entered into a partnership with a major Texas university to advance its research.

"We've actually been working on the antiviral potential of WP1122 for some time now," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "but the rise of COVID-19 has obviously placed a new sense of urgency on what we are doing. We hope to be generating animal data on WP1122's antiviral potential in the near term."

Pulmotech Inc.

Pulmotect, a clinical-stage biotechnology company based in Houston, is testing a drug that could be useful in mitigating the threats of the coronavirus, which is currently been recognized as a global health emergency. Getty Images

Experiments conducted by clinical-stage, Houston-based biotechnology company Pulmotect Inc. show its PUL-042 inhaled drug has proven effective in protecting mice against two types of coronavirus: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Researchers performed those tests at the University of Texas Medical Branch at Galveston.

In the Galveston experiments, a single inhaled dose of PUL-042 protected lab mice from the SARS virus, and it greatly reduced the amount of virus in their lungs after the mice became infected with SARS or MERS.

"With the risks of virulent coronaviruses and other threats increasing, as shown by the recent outbreak in Wuhan that has already spread from China to other countries including the United States, Pulmotect is optimistic that its immune-stimulating technology could be useful in mitigating the threats of current and emerging pathogens and protecting vulnerable populations," says CEO Dr. Colin Broom in a news release. Click here to read more.

Houston biotech company is creating a drug that could fight the coronavirus

Med tech

A drug being developed by a Houston biopharmaceutical company eventually could help combat what the World Health Organization has proclaimed a global health emergency.

Experiments conducted by clinical-stage biotechnology company Pulmotect Inc. show its PUL-042 inhaled drug has proven effective in protecting mice against two types of coronavirus: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Researchers performed those tests at the University of Texas Medical Branch at Galveston.

The ability of PUL-042 to ward off the newest type of coronavirus, 2019-nCoV, hasn't been tested yet. However, the drug eventually could help prevent the new virus from spreading, says Broom, who joined Pulmotect as CEO last fall. A separate study would be required to evaluate PUL-042 in patients exposed to 2019-nCoV, he says.

"PUL-042 has the potential to prevent and treat respiratory complications in many high-risk patient populations, including those where no effective therapies are currently available, as is the case with the current coronavirus outbreak," Brenton Scott, president and chief operating officer of Pulmotect, says in the release.

Since its discovery in late December 2019 in Wuhan, China, nearly 9,800 people around the world were infected with 2019-nCoV as of January 31, The New York Times reported. Of those people, more than 200 died. On January 30, the World Health Organization (WHO) declared the virus outbreak a global health emergency.

No specific treatment or cure for 2019-nCoV virus is available. This virus is among seven known coronaviruses.

Symptoms of the Wuhan coronavirus include fever, cough, and shortness of breath, according to the U.S. Centers for Disease Control and Prevention (CDC). The virus can cause pneumonia, SARS, kidney failure, or even death, the Virginia Department of Health says.

PUL-042 "would be a great tool to have available for future outbreaks and epidemics, in addition to being used more routinely for more common infections," Broom says.

Fighting coronaviruses is a potential byproduct of PUL-042.

Initially, Pulmotect is focusing development of PUL-042 on the prevention and treatment of respiratory complications suffered by cancer patients with suppressed immune systems. Phase 1 clinical trials already have taken place in the U.S., and Phase 2 clinical trials are scheduled for later this year.

A separate trial of PUL-042 is underway in London. There, the drug is being tested on patients with chronic obstructive pulmonary disease (COPD) who are prone to lung infections. COPD is an inflammatory disease that blocks airflow from the lungs. People with COPD face a heightened risk of conditions like heart disease and lung cancer, the Mayo Clinic says.

Broom says PUL-042 is a few years away from being considered for approval by the U.S. Food and Drug Administration (FDA).

To date, Pulmotect has raised more than $28 million in outside funding. Founded in 2007, Pulmotect emerged from Houston's Fannin Innovation Studio, which nurtures early stage companies in the life sciences sector.

Patents for PUL-042, invented by MD Anderson Cancer Center and Texas A&M University, have been issued in nine countries.

A Houston biotech company has a new CEO and is ready for growth. Getty Images

Houston biopharmaceutical company brings on new CEO to grow company

Head honcho

With a veteran of the biopharmaceutical industry now aboard as its CEO and an executive at pharmaceutical giant AstraZeneca now serving on its board, Houston-based biopharmaceutical company Pulmotect Inc. is poised for progress.

In September, Dr. Colin Broom joined Pulmotect as CEO. He previously was CEO of Ireland-based Nabriva Therapeutics plc, a biopharmaceutical company that went public in 2015. During Broom's tenure at Nabriva, he helped develop the recently approved drug Xenleta, which treats bacterial pneumonia. Before that, he was chief scientific officer at Pennsylvania-based pharmaceutical company ViroPharma Inc., which Massachusetts-based Shire plc purchased for $4.2 billion in 2014.

Broom's hiring came on the heels of Kumar Srinivasan being named to Pulmotect's board of directors. Srinivasan is vice president of United Kingdom-based AstraZeneca and is its global head of business development and licensing for biopharmaceuticals R&D.

Researchers at MD Anderson Cancer Center and Texas A&M University invented Pulmotect's main product, PUL-042, which holds patents in nine countries. Pulmotect, founded in 2007, emerged from Houston's Fannin Innovation Studio, which nurtures early stage companies in the life sciences sector.

"Attracting such a highly regarded and proven CEO as Colin is a clear signal of the power and potential of Pulmotect's development program," Pulmotect's executive chairman, Leo Linbeck III, founder and chairman of Fannin, says in a release. "Under his leadership, I'm confident that we will advance our technology further into the clinic and closer to the marketplace. His addition is a real game-changer for the company."

Both Broom and Srinivasan are focusing on clinical trials for Pulmotect's PUL-042 product, an inhaled therapy that holds the potential to prevent or treat respiratory infections caused by bacteria, viruses, or fungi. The current Phase 2 trial is evaluating the effectiveness of PUL-042 in treating patients with mild chronic obstructive pulmonary disease (COPD) who've been exposed to a respiratory virus. The current trial is supposed to be followed by additional Phase 2 trials.

COPD, which affects 30 million Americans, is the No. 3 cause of death in the U.S., according to the COPD Foundation. Pulmotect says 40 percent of COPD-related costs could be avoided by preventing complications and hospitalizations, which typically result from COPD problems triggered by a bacterial or viral infection. PUL-042 could substantially decrease those complications, the company says.

Pulmotect seeks to gear PUL-042 toward patients with cancer who are undergoing chemotherapy, as their weakened immunity makes them highly susceptible to pneumonia, Broom says. If the product proves effective with those patients, then people at risk of developing respiratory infections also might benefit from it, including COPD patients and flu patients, he says.

To date, Pulmotect has raised more than $28 million in funding. That includes about $18 million in research grants, including a $7 million grant from the Cancer Prevention and Research Institute of Texas, as well as seven grants from the Small Business Innovation Research program.

Two of Pulmotect's three full-time employees work in Houston, and a team of consultants supports their work, Broom says. A small number of employees might be added during the current Phase 2 trial. Hiring would need to be ramped up if the Phase 2 trial demonstrates that PUL-042 works, he says.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston startup grows C-suite, Deloitte opens awards apps, SDO names leader, and more innovation news

short stories

The Houston innovation ecosystem has been especially busy this year, and for this reason, local startup and tech news may have fallen through some of the cracks.

In this roundup of short stories within Houston innovation, local organizations announce new innovators, Deloitte opens apps for its annual tech awards, Houston Tech Rodeo prepares for its annual events, and more.

Early stage accelerator names new Houston leader

Kate Evinger will lead gBETA Houston. Photo via LinkedIn

A Houston early-stage startup accelerator has named its new director. Kate Evinger has joined gener8tor's gBETA Houston as director. She will run the third gBETA cohort in Houston, adding to the 10 alumni from the two cohorts held in 2020.

Evinger has replaced Anu Pansare, who was previously named director in February. Pansare, who replaced the accelerator's inaugural director Eléonore Cluzel, moved on to another opportunity, Evinger says.

Based in Houston's Downtown Launchpad, gBETA's third cohort of early stage startups will soon start its free 7-week program, which is designed to help participating companies gain early customer traction and develop key metrics that will make them more marketable for future investment.

Evinger has been a part of the gener8tor family since 2016 when she joined the team as associate for gBETA Madison. She was promoted to program manager in 2019 when she graduated from Indiana University with degrees in finance, entrepreneurship and corporate innovation, according to a news release.

"Downtown Launchpad's inclusive set of tools, resources and opportunities empower Houston founders to accelerate and scale their businesses to solve humankind's boldest challenges," says Robert Pieroni, director of economic development at Central Houston, in a news release. "Kate Evinger brings experience and valuable insights to the gBETA Houston program and will help us continue to support founders, Houston-based partners and the community."

Houston Tech Rodeo launches registration and names headliner

Master P will be the headlining guest for Houston Tech Rodeo. Photo courtesy of HTR

Houston Tech Rodeo, a week-long collaboration of events hosted by Houston Exponential, has opened registration and announced Percy Miller, also known as musical artist Master P, as the headliner.

Miller, who began his career as an international rap artist, later became a CEO, investor, and founder of Nemesis RR.

"I'll be sharing my journey, my secrets, my success, my feelings, and my rebuilding. Transitioning from international artist to CEO to investing in philanthropy, I want to educate you and give you that gain," says Miller in a news release. "I want to add diversity into technology and the automotive industry."

HTR kicks off May 16 at Saint Arnold Brewing Company with live music, beer, and swag bag pick ups with registration. The week concludes on May 23. Registration is free and available online.

Houston industrial blockchain company expands C-suite

Data Gumbo has a new C-level executive. Photo courtesy of Data Gumbo

Data Gumbo, a Houston-based industrial smart contract network powered by blockchain — announced that it has brought on Robin Macmillan as chief corporate development officer to lead the company's corporate development team.

"The sheer breadth of Macmillan's experience will serve as an invaluable asset to Data Gumbo as we continue to exponentially grow and mature our company into new industrial markets and further solidify our leadership in energy," says Andrew Bruce, CEO and founder of Data Gumbo, in a news release. "Macmillan has the experience to expand Data Gumbo's commercial market penetration to aid companies in undertaking digital transformation with smart contracts to reveal streamlined efficiencies and cost savings, sustainability insights across supply chains and transactional certainty in any commercial relationship."

Macmillan has over 40 years of experience in the energy industry, most recently at National Oilwell Varco and is the vice president of drilling services at the International Association of Drilling Contractors,

"There is tremendous opportunity right now to change how business is executed," says Macmillan in the release. "Data Gumbo is poised to deliver trust through automated, auditable blockchain-backed smart contracts that execute transactions in real-time. I am thrilled to be a part of the Data Gumbo executive team as the company is in a period of hyper growth into new industries, serving as a harbinger for significant digital transformation across commercial relationships and transparent, accurate sustainability impact data."

Deloitte opens annual tech awards nominations

Calling all fast-growing tech companies. Image via Deloitte

Deloitte's Technology Fast 500 awards — which celebrate the fastest growing, most innovative technology, media, telecommunications, life sciences and energy tech companies in the country — has opened applications for its 2021 program.

Applications opened online on April 9 and will remain open until June 29. Winners will be announced on November 15. The program ranks applicants based on percentage of fiscal year revenue growth and the list is compiled from applications. For more information, visit the Technology Fast 500 website.

"Each year, we are excited to see the variety of Houston's Fast 500 applicants, which represent the city's positive momentum in both diversifying its core competencies and highlighting the boom in technology innovations coming to market," says Amy Chronis, vice chair and Houston managing partner at Deloitte LLP. "We look forward to seeing what Houston's innovators will bring in 2021."

Energy incubator announces latest cohort

Fifteen energy startups are joining the Plug and Play family. Gif courtesy of Plug and Play

Plug and Play Tech Center has announced 154 startups into its 2021 summer program — 15 of which were named to the Houston-based Batch 8 Energy Program. During the course of the next three months, these companies will receive access to our corporate, venture capital, and mentor network.

The new energy cohort consists of the following companies:

Texas expert: Energy reliability and climate sustainability are not mutually exclusive

Guest Column

It's no secret that Texas has long been a leader in energy production, but it may surprise you to learn that Texas leads the nation in wind-powered generation, producing 28 percent of all US wind-powered electricity in 2019.

We're not just producing a lot of renewable energy, we're increasingly consuming it.

Contrary to the caricaturistic portrayal of Texans in mainstream culture, a recent study by the University of Houston revealed that 4 out of 5 Texans believe the climate crisis is real.

In an effort to reduce their carbon footprint, more and more households are making the decision to switch to 100 percent renewable energy. And this adoption isn't isolated to core urban areas. We're witnessing a diverse spread in smaller, more rural markets.

These reasons and more are why Bulb, one of Europe's fastest growing company that provides 100 percent renewable energy, chose Texas as its first home in the U.S. Less than a year after launching here, it's safe to say we made the right choice as we're experiencing even faster growth in Texas than we did in our early stages in the United Kingdom.

One of the many reasons Texans have rapidly adopted our simpler, cheaper and greener energy is because they no longer have to choose between being budget and climate conscious. Sadly, the progress the state has made could be knocked back following the recent winter storm.

After the nation witnessed Texas' massive outages during the winter storm, our state leaders understandably feel the pressure to "do something," quickly.

We share our leaders' determination in avoiding another crisis of this magnitude, but we fear that Texas may be heading in the wrong direction. In the mad rush to avoid another catastrophe, some regulators and politicians wrongly and disproportionately blamed renewable energy sources for the outages.

Numerous media outlets and energy experts have overwhelmingly refuted these claims. An AP fact check described the efforts to blame renewable energy sources as "false narratives." And, they're not alone in their conclusion.

According to Reuters' fact check, "These claims are misleading, as they shift blame for the crisis away from what appears, so far, to be the root cause...The state's woes mainly stem from issues surrounding its independent power grid. The cold weather affected all fuel types, not just renewables."

Determining what went wrong isn't a blame game. A proper diagnosis is essential to any problem solving. And a failure to conduct a thorough analysis could have serious consequences. Currently, a number of legislative solutions are floating around the state Capitol that would shift the blame and consequences to renewable energy.

These proposals would increase the financial burden on Texas consumers, many of whom are still recovering from the storm, and hamper new investments in renewable energy. Additionally, and perhaps even more concerning, they don't adequately address the root cause of the winter storm energy crisis, further exposing Texans to another meltdown.

Texas' leadership on renewable energy production is no small feat, and it didn't happen by chance. For two decades, our lawmakers have made strategic decisions that led to the advancement of renewable energy production, and it has paid dividends in terms of jobs, economic growth, energy reliability, sustainability and even the state's reputation.

We are at a critical juncture, but Texas doesn't have to choose between reliability, affordability and sustainability. We can offer reliable energy and green energy, stop another crisis before it happens again and move forward with renewable energy investments.

Continuing to promote policies that pushed Texas to its leadership position will unleash even more investments and innovation, which is good for Texas, good for Texans and good for the planet.

As we observe Earth Day, we would urge our leaders to consider the possibilities. Rather than turn the clock back, let's use this storm as an opportunity to innovate further.

------

Vinnie Campo is the general manager for Bulb U.S., a new type of energy company that aims to make energy simpler, cheaper, and greener by providing renewable electricity to its members from Texas wind and solar. He is based in Texas.

Houston-based software startup aims to connect workers with wages in real time

there's an app for that

Could you incur an unexpected $400 expense if it hit your bank account today? According to Jeff Price, founder and CEO of Houston-based Pronto Pay, many hourly workers could not. He's set out to change that.

"When you think about it, payroll hasn't changed in nearly two centuries. As far as we can remember, you get paid weekly or bi-weekly. And that's precisely the point we're trying to solve," Price says.

A recent graduate from Rice University's Jones Graduate School of Business, Price founded Pronto Pay in the first quarter of 2021. The software aims to connect hourly works with transparent access to wages earned before pay day without disrupting the employers' books. Currently the company has seven staff members, is actively hiring and is looking to expand outside of Houston soon.

Pronto Pay partners with the employers to seamlessly build out connections with their time and attendance system and payroll processor. After the company signs up, ProntoPay automatically creates an account for each employee, which allows them to view their accrued wages and withdraw their earnings instantly from the app or next-day for automated clearing house payments — all via the Pronto Pay App. When an employee wishes to withdraw funds prior to their normal pay cycle, Pronto Pay applies a small fixed fee — $2.99 — for completing the transaction. .

Come pay day, the employer's system will automatically balance the difference and route the withdrawn money back to Pronto Pay. As Price describes it, Pronto Pay aims to compete "directly with (while severely undercutting the price of) payday and other predatory lenders."

The idea was born out of a series of simple questions Price started to ask himself when he envisioned what his newborn son's first job would be earlier this year.

"My wife and I were having our son and it challenged me to ask questions like, 'Hey, why do we get paid bi-weekly? If I can Venmo 100 bucks in real time, why can't a company do that?'" Price recalls.

Apart from the impact of advanced pay, Price envisions that earned wages access will improve workplace culture and retention, too. Pronto Pay has already on-boarded users in the local staffing and warehousing markets, in the janitorial and security guard fields, and at call centers. As Price describes, Pronto Pay's clients "typically have a lot of hourly employees that struggle with employee retention and keeping folks at the same job for longer than three to 12 months."

"We're hoping that we can permanently change that employee-employer relationship," he adds. "And help those employees."

Jeff Price is the founder and CEO of Pronto Pay.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME